A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink
- PMID: 36535825
- PMCID: PMC9755007
- DOI: 10.1016/j.vaccine.2022.12.026
A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink
Abstract
Background: Except for spontaneous reporting systems, vaccine safety monitoring generally involves pre-specifying health outcomes and post-vaccination risk windows of concern. Instead, we used tree-based data-mining to look more broadly for possible adverse events after Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccination.
Methods: Vaccine Safety Datalink enrollees receiving ≥1 dose of COVID-19 vaccine in 2020-2021 were followed for 70 days after Pfizer-BioNTech or Moderna and 56 days after Janssen vaccination. Incident diagnoses in inpatient or emergency department settings were analyzed for clustering within both the hierarchical ICD-10-CM code structure and the post-vaccination follow-up period. We used the self-controlled tree-temporal scan statistic and TreeScan software. Monte Carlo simulation was used to estimate p-values; p = 0.01 was the pre-specified cut-off for statistical significance of a cluster.
Results: There were 4.1, 2.6, and 0.4 million Pfizer-BioNTech, Moderna, and Janssen vaccinees, respectively. Clusters after Pfizer-BioNTech vaccination included: (1) unspecified adverse effects, (2) common vaccine reactions, such as fever, myalgia, and headache, (3) myocarditis/pericarditis, and (4) less specific cardiac or respiratory symptoms, all with the strongest clusters generally after Dose 2; and (5) COVID-19/viral pneumonia/sepsis/respiratory failure in the first 3 weeks after Dose 1. Moderna results were similar but without a significant myocarditis/pericarditis cluster. Further investigation suggested the fifth signal group was a manifestation of mRNA vaccine effectiveness after the first 3 weeks. Janssen vaccinees had clusters of unspecified or common vaccine reactions, gait/mobility abnormalities, and muscle weakness. The latter two were deemed to have arisen from confounding related to practices at one site.
Conclusions: We detected post-vaccination clusters of unspecified adverse effects, common vaccine reactions, and, for the mRNA vaccines, chest pain and palpitations, as well as myocarditis/pericarditis after Pfizer-BioNTech Dose 2. Unique advantages of this data mining are its untargeted nature and its inherent adjustment for the multiplicity of diagnoses and risk intervals scanned.
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest WK Yih has received research funding from Pfizer in the past. JC Nelson received grant funding to participate on the External Safety Advisory Board for Moderna’s COVID-19 vaccine program in 2020 – April 2021. L Qian has received funding from Moderna, GlaxoSmithKline, and Dynavax for work unrelated to this manuscript. The other authors report no conflicts.
Similar articles
-
Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink.Vaccine. 2023 Jan 9;41(2):460-466. doi: 10.1016/j.vaccine.2022.11.053. Epub 2022 Nov 24. Vaccine. 2023. PMID: 36481108 Free PMC article.
-
Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink.Vaccine. 2023 Aug 14;41(36):5265-5270. doi: 10.1016/j.vaccine.2023.07.010. Epub 2023 Jul 20. Vaccine. 2023. PMID: 37479610
-
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.BMJ. 2022 Jul 13;378:e069445. doi: 10.1136/bmj-2021-069445. BMJ. 2022. PMID: 35830976 Free PMC article. Review.
-
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099. doi: 10.15585/mmwr.mm7032e4. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34383735 Free PMC article.
-
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877. Eur Rev Med Pharmacol Sci. 2021. PMID: 33629336 Review.
Cited by
-
Risk of cardiac arrhythmia and cardiac arrest after primary and booster COVID-19 vaccination in England: A self-controlled case series analysis.Vaccine X. 2023 Dec 1;15:100418. doi: 10.1016/j.jvacx.2023.100418. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38090643 Free PMC article.
-
Comparison of Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations.TH Open. 2023 Dec 4;7(4):e303-e308. doi: 10.1055/a-2183-5269. eCollection 2023 Oct. TH Open. 2023. PMID: 38053618 Free PMC article.
-
Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink.Vaccine. 2023 Jan 9;41(2):460-466. doi: 10.1016/j.vaccine.2022.11.053. Epub 2022 Nov 24. Vaccine. 2023. PMID: 36481108 Free PMC article.
References
-
- Rosenblum H.G., Gee J., Liu R., Marquez P.L., Zhang B., Strid P., et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. Lancet Infect Dis. 2022;22:802–812. doi: 10.1016/S1473-3099(22)00054-8. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical